Recently, it was reported that the over-expression of COX-2 in cancer cells, relative to normal adjacent tissue where COX-2 is not expressed, constitutes a logical molecular diagnostic design strategy to discover non-invasive diagnostic agents to detect tumours, and the subsequent monitoring of disease progression and/or treatment efficacy [20,21]. Here, PTGS2 is linked to neoplasm.